Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18,776 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy.
Wadsley J, Ainsworth G, Coulson AB, Garcez K, Moss L, Newbold K, Farnell K, Swain J, Howard H, Beasley M, Weaver A, Wood K, Marshall J, Griffin M, Pascoe A, Du Y, Taprogge J, Flux G, Brown S. Wadsley J, et al. Among authors: du y. Thyroid. 2023 Sep;33(9):1119-1123. doi: 10.1089/thy.2022.0707. Epub 2023 Sep 1. Thyroid. 2023. PMID: 37565288 Free PMC article. Clinical Trial. No abstract available.
The Predictive Value of Early Assessment After 1 Cycle of Induction Chemotherapy with 18F-FDG PET/CT and Diffusion-Weighted MRI for Response to Radical Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma.
Wong KH, Panek R, Welsh L, Mcquaid D, Dunlop A, Riddell A, Murray I, Du Y, Chua S, Koh DM, Bhide S, Nutting C, Oyen WJ, Harrington K, Newbold KL. Wong KH, et al. Among authors: du y. J Nucl Med. 2016 Dec;57(12):1843-1850. doi: 10.2967/jnumed.116.174433. Epub 2016 Jul 14. J Nucl Med. 2016. PMID: 27417648 Free article. Clinical Trial.
Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival.
Denis-Bacelar AM, Chittenden SJ, Dearnaley DP, Divoli A, O'Sullivan JM, McCready VR, Johnson B, Du Y, Flux GD. Denis-Bacelar AM, et al. Among authors: du y. Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):620-629. doi: 10.1007/s00259-016-3543-x. Epub 2016 Oct 21. Eur J Nucl Med Mol Imaging. 2017. PMID: 27770145 Free PMC article.
SELIMETRY-a multicentre I-131 dosimetry trial: a clinical perspective.
Wadsley J, Gregory R, Flux G, Newbold K, Du Y, Moss L, Hall A, Flanagan L, Brown SR. Wadsley J, et al. Among authors: du y. Br J Radiol. 2017 May;90(1073):20160637. doi: 10.1259/bjr.20160637. Epub 2017 Mar 14. Br J Radiol. 2017. PMID: 28291381 Free PMC article. Clinical Trial.
Reply to 'Single high dose versus repeated bone-targeted radionuclide therapy'.
Denis-Bacelar AM, Chittenden SJ, Dearnaley DP, Divoli A, O'Sullivan JM, McCready VR, Johnson B, Du Y, Flux GD. Denis-Bacelar AM, et al. Among authors: du y. Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):515-517. doi: 10.1007/s00259-017-3902-2. Eur J Nucl Med Mol Imaging. 2018. PMID: 29247283 No abstract available.
Dosimetry-based treatment for Graves' disease.
Hyer SL, Pratt B, Gray M, Chittenden S, Du Y, Harmer CL, Flux GD. Hyer SL, et al. Among authors: du y. Nucl Med Commun. 2018 Jun;39(6):486-492. doi: 10.1097/MNM.0000000000000826. Nucl Med Commun. 2018. PMID: 29613968 Free PMC article.
Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial.
Brown SR, Hall A, Buckley HL, Flanagan L, Gonzalez de Castro D, Farnell K, Moss L, Gregory R, Newbold K, Du Y, Flux G, Wadsley J. Brown SR, et al. Among authors: du y. BMC Cancer. 2019 Jun 14;19(1):582. doi: 10.1186/s12885-019-5541-4. BMC Cancer. 2019. PMID: 31200667 Free PMC article.
18,776 results
You have reached the last available page of results. Please see the User Guide for more information.